GILDCL logo

Gilead Sciences SNSE:GILDCL Stock Report

Last Price

CL$79.00k

Market Cap

CL$119.0t

7D

0%

1Y

n/a

Updated

01 Feb, 2025

Data

Company Financials +

Gilead Sciences, Inc.

SNSE:GILDCL Stock Report

Market Cap: CL$119.0t

GILDCL Stock Overview

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details

GILDCL fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance1/6
Financial Health3/6
Dividends3/6

My Notes

Capture your thoughts, links and company narrative

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Gilead Sciences
Historical stock prices
Current Share PriceUS$79,000.00
52 Week HighUS$92,381.00
52 Week LowUS$72,660.00
Beta0.20
1 Month Change0%
3 Month Change0%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO8.73%

Recent News & Updates

Recent updates

Shareholder Returns

GILDCLCL BiotechsCL Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how GILDCL performed against the CL Biotechs industry.

Return vs Market: Insufficient data to determine how GILDCL performed against the CL Market.

Price Volatility

Is GILDCL's price volatile compared to industry and market?
GILDCL volatility
GILDCL Average Weekly Movement0%
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in CL Market0%
10% least volatile stocks in CL Market0%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine GILDCL's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
198718,000Dan O'Daywww.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILDCL fundamental statistics
Market capCL$118.96t
Earnings (TTM)CL$123.73b
Revenue (TTM)CL$27.79t

961.4x

P/E Ratio

4.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GILDCL income statement (TTM)
RevenueUS$28.30b
Cost of RevenueUS$6.28b
Gross ProfitUS$22.02b
Other ExpensesUS$21.89b
EarningsUS$126.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 11, 2025

Earnings per share (EPS)0.10
Gross Margin77.80%
Net Profit Margin0.45%
Debt/Equity Ratio126.4%

How did GILDCL perform over the long term?

See historical performance and comparison

Dividends

3.2%

Current Dividend Yield

3,027%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 18:43
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gilead Sciences, Inc. is covered by 73 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research